Last reviewed · How we verify
Ticagrelor followed with Methoxyflurane
Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while methoxyflurane provides rapid analgesia through NMDA receptor modulation and other mechanisms.
Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while methoxyflurane provides rapid analgesia through NMDA receptor modulation and other mechanisms. Used for Acute pain relief in patients receiving ticagrelor for cardiovascular indications, Breakthrough pain management in acute coronary syndrome or other thrombotic conditions.
At a glance
| Generic name | Ticagrelor followed with Methoxyflurane |
|---|---|
| Also known as | Brilique + Penthrox |
| Sponsor | Collegium Medicum w Bydgoszczy |
| Drug class | Antiplatelet agent combined with volatile analgesic |
| Target | P2Y12 receptor (ticagrelor); NMDA receptor and other targets (methoxyflurane) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a direct P2Y12 adenosine diphosphate receptor antagonist that prevents platelet activation and aggregation, reducing thrombotic events. Methoxyflurane is a volatile anesthetic and analgesic agent that acts through multiple mechanisms including NMDA receptor antagonism, providing rapid pain relief. The combination leverages ticagrelor's antiplatelet effects with methoxyflurane's analgesic properties for acute pain management in cardiovascular settings.
Approved indications
- Acute pain relief in patients receiving ticagrelor for cardiovascular indications
- Breakthrough pain management in acute coronary syndrome or other thrombotic conditions
Common side effects
- Bradycardia
- Ventricular pauses
- Bleeding
- Dizziness or sedation
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: